Rediscovering hemostasis abnormalities in multiple myeloma: The new era
Open Access
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82300151)
- National Health Commission of the People's Republic of China (KJS2344)
This publication has 123 references indexed in Scilit:
- Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)Annals of Hematology, 2022
- Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myelomaAmerican Journal of Hematology, 2021
- A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohortAmerican Journal of Hematology, 2021
- Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysisInternational Journal of Hematology, 2020
- Acquired dysfibrinogenemia: monoclonal λ-type IgA binding to fibrinogen caused lower functional plasma fibrinogen level and abnormal clot formationInternational Journal of Hematology, 2020
- Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta‐analysis of cohort studiesInternational Journal of Cancer, 2019
- Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for cliniciansJournal of Thrombosis and Thrombolysis, 2017
- Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma TherapiesJAMA Oncology, 2017
- Hyperlipidemic myeloma: review of 53 casesAnnals of Hematology, 2009
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureThe JNC 7 ReportJAMA, 2003